Investors sent shares of Micrologix Biotech Inc. to a 52-week low yesterday after the company abandoned early testing of a drug to treat antibiotic-resistant superbugs. "While the suspension of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results